Credo needs a slightly lower price before adding. FY28 EPS of about $10, a 70% growth rate from today, would support a $350 stock at 35x, a 0.5x PEG. x.com 

Credo is buying its re-acceleration at a flat gross margin, and at 36 times forward earnings, growth without margin is worth less. Q2 revenue guidance of $525-535M topped the $514.7M consensus, but non-GAAP gross margin went 68.6%, 68.3%, 68.0% and is guided at 67-69% again, while the beat over estimates shrank from 41% to 0.8%. Three customers are 77% of revenue. Credo sells copper, and Marvell expects scale-up optics from 2027. A print above 69% on $530M would prove this too cautious. x.com  … Show more

Credo's valuation is not absurd relative to its growth. The latest selloff is another overreaction. x.com  x.com 

Credo's upside looks capped as growth falls short of earlier expectations and large stock-based compensation, hidden behind GAAP financials, looks excessive. BofA cut its target to $275 from $340 and Evercore to $292 from $325 on deceleration worries, the 1.6T DSP is delayed, and operating cash flow fell to $90M. The stock is 43% off its high; at $164 it trades at 30-33x FY27 earnings and 13x forward sales, more reasonable but still not worth owning. x.com  x.com  x.com  x.com 

Credo's results were underwhelming for a company that added $32 billion in market value in a few months, and shorts may punish the stock. Per @WisemanCap, fiscal Q4 EPS of $1.16 beat the $1.02 estimate and revenue of $437 million was just above estimates, while Q1 fiscal 2027 revenue guidance of $465-476 million was roughly in line with the $464.7 million consensus. x.com  x.com 

Credo's near-total share of AI data-center cables and unchanged estimates make its lower multiple look like a fear-driven opportunity. Its stock went from 27x to 20x forward earnings while the supply chain building those systems guided 2027 revenue to double. Buyers this week will probably be very happy a year from now. x.com 

Credo's 11% drop on its promotion to the Russell 1000 was index plumbing, but falling twice as much as chips exposed its fragility: at 33x sales with three customers making up 88% of revenue, it is vulnerable. Forced Russell 2000 selling met only a teaspoon of large-cap index buying. Holding $236 and reclaiming $241 targets a $252 gap fill; losing $231 means real sellers. The next print, around early September, decides it: falling concentration makes it a trade, 88% staying means fade the rip. … Show more

Cerebras is likely heading lower after terrible earnings, with share unlocks about to add supply. Its valuation was so stretched that it couldn't afford a miss, and it apparently missed; a lot of hope was already built into the price. It could trade around $150 soon. x.com  x.com  x.com  x.com 

Credo's repeatedly conservative guidance and quarterly beats suggest analysts understate next year's EBIT. It trades at 15x their estimate, but likely 12-13x next year's EBIT if management's guidance holds. Management has executed as well as almost any company in recent years, and the multiple could easily end up closer to 10x than 15x. x.com 

Astera Labs is an incredible business, but its price leaves little margin of safety. Even an amazing decade, with revenue reaching $20B at 26% annual growth from about $1.9B, a 35% operating margin and a 30x multiple, makes it a roughly $158B company, about 3.6x from $44B, or around 13% a year before dilution. Slower revenue, lower margins, a lost customer, hyperscaler insourcing or tougher competition would erode that. Buying at half the price would make the risk/reward look amazing. x.com  … Show more